Clinical trials
Chronic Leukemia clinical trials
Below are recruiting chronic leukemia clinical trials, each written for real people, not researchers. We’re tracking 303 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03765177RecruitingPhase 1/Phase 2
CLIC-1901 for CD19-positive blood and lymphoma cancers
This trial studies a gene-modified cell treatment called CLIC-1901 for people whose CD19-positive cancer has come back or did not respond to prior treatment. It may help shrink the cancer by targeting a protein called CD19 on cancer cells.
Vancouver, British ColumbiaAges 18–75 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT05584761RecruitingPhase 1/Phase 2
Cord blood stem cells plus azacitidine for advanced blood cancers
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Nanjing, JiangsuAges 18–80 - NCT07566364RecruitingPhase 2
Mosunetuzumab for Chronic Lymphocytic Leukemia with Minimal Residual Disease
This study tests a new antibody drug called mosunetuzumab in patients with chronic lymphocytic leukemia (CLL) who have already tried other treatments and still have detectable leukemia cells in their bone marrow. The drug is designed to work in a way that might help your immune system fight the remaining cancer cells.
Houston, TexasAges 18 years+ - NCT07218341RecruitingPhase 4
Continuing pirtobrutinib for CLL or SLL patients
This trial continues treatment with the drug pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already in another study. It is not open to new patients.
Mobile, AlabamaAges 18 years+ - NCT06588478RecruitingPhase 2
Study of pirtobrutinib for CLL or SLL
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
Chandler, ArizonaAges 18 years+ - NCT05371808Recruiting
Early vs delayed treatment for high-risk CLL: cost study
This study compares early treatment versus delaying treatment in newly diagnosed people with high-risk CLL/SLL who feel well. It mainly looks at the overall “costs and value” of each approach and asks patients to complete short health and quality-of-life questionnaires.
Vancouver, British ColumbiaAges 18 years+ - NCT05025774Recruiting
Exercise program study for young heart, leukemia, and lung survivors
This study looks at how an exercise program affects fitness and lung function in young people who are survivors of certain conditions (heart transplant, leukemia, or lung disease from prematurity). The goal is to see whether exercise can improve breathing and overall physical function safely.
Minneapolis, MinnesotaAges 8–25 - NCT07474051Enrolling by invitation
Long-term follow-up for CAR-T cell therapy patients
This study tracks people who received a specific CAR-T cell therapy made by AvenCell. The goal is to monitor their health over time to better understand long-term effects.
BerlinAges Any age - NCT05536349RecruitingPhase 2
Testing three drug combo for untreated CLL or CLL-related cancer
This Phase 2 study tests pirtobrutinib plus venetoclax plus obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL) or CLL-related Richter transformation (RT). The goal is to see if this “triplet” combination works better and is safe enough to control the disease.
Houston, TexasAges 18 years+ - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years - NCT05557695Recruiting
Acalabrutinib patient study for early access CLL in the UK
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
AylesburyAges 18–130 - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT05645510Recruiting
Study for people on long-term cancer targeted medicines
This study looks at people who are already taking long-term targeted cancer medicines. It may help researchers understand how these treatments work over time and whether there are ways to improve care.
Edmonton, AlbertaAges 18–90 - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Laguna Hills, CaliforniaAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT06978088RecruitingPhase 2
A study of LP-168 and obinutuzumab for CLL/SLL
This trial tests a new combination of two drugs, LP-168 and obinutuzumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose disease has come back or not responded to previous treatments. It may be an option if you have already tried certain therapies, including a BTK inhibitor or a BCL2 inhibitor.
Cincinnati, OhioAges 18 years+ - NCT04867915Recruiting
Study of CLL, SLL, and related blood conditions in Italy
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
AlessandriaAges 18 years+ - NCT06876662RecruitingPhase 4
Continuing pirtobrutinib for CLL and lymphoma patients
This trial continues to give pirtobrutinib to people with chronic lymphocytic leukemia or certain other lymphomas who were already in a previous study with this drug. It helps researchers keep track of long-term safety and how well the drug works over time.
Miami, FloridaAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT06398457RecruitingEarly Phase 1
Darzalex Before Stem Cell Transplant for High-Risk Graft Failure
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Baltimore, MarylandAges 18 years+ - NCT06812715RecruitingPhase 2
Pirtobrutinib after zanubrutinib for chronic lymphocytic leukemia
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
Melbourne, VictoriaAges 18 years+ - NCT06646978Enrolling by invitation
Long-term cancer risk in CML treatment trial
This study follows people who took part in the French SPIRIT trial for chronic myeloid leukemia (CML) to see if they develop other cancers later in life. It helps doctors understand the long-term safety of imatinib-based treatments.
PoitiersAges 18 years+ - NCT04935684RecruitingPhase 2
Fecal transplant after bone marrow transplant to improve gut health
This Phase 2 study tests whether a fecal microbiota transplant (a processed transplant of gut bacteria) after an allogeneic bone marrow transplant is safe and helpful. Participants may benefit by improving recovery in the gut microbiome during the post-transplant period.
AmiensAges 18 years+
Hear when a new Chronic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic leukemia?
- Yes. Clin2 currently lists 303 recruiting chronic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.